Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $6.63

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned an average recommendation of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $6.63.

TSHA has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th.

Taysha Gene Therapies Stock Down 15.3 %

NASDAQ TSHA opened at $2.61 on Friday. The stock has a market cap of $534.89 million, a PE ratio of 4.14 and a beta of 0.79. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The stock’s 50 day moving average is $2.09 and its 200 day moving average is $2.38. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of TSHA. Quantum Private Wealth LLC grew its position in Taysha Gene Therapies by 4.6% in the 2nd quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock valued at $1,636,000 after acquiring an additional 32,000 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Taysha Gene Therapies in the 2nd quarter valued at $1,018,000. Principal Financial Group Inc. bought a new position in Taysha Gene Therapies in the 2nd quarter valued at $48,000. Privium Fund Management B.V. bought a new position in Taysha Gene Therapies in the 2nd quarter valued at $213,000. Finally, Rhumbline Advisers bought a new position in Taysha Gene Therapies in the 2nd quarter valued at $413,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.